CONTROLLED RELEASE DRUG DELIVERY MARKET Size and trends

Controlled Release Drug Delivery Market Size and Trends

Global controlled release drug delivery market is estimated to be valued at USD 58.18 Bn in 2025 and is expected to reach USD 119.34 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 10.8% from 2025 to 2032.

To learn more about this report, Request sample copy

Controlled release drug delivery helps in improving patient compliance and treatment effectiveness by releasing the drug at a predetermined rate and targeting specific sites of action. It helps in minimizing side effects and reducing frequency of dosing through continuous supply of medication over extended period of time. Growing preference for controlled release products to conventional drug formulations due to their various advantages such as better management of chronic diseases can drive the market growth. Increasing investment by market players to develop advanced controlled release injectable and transdermal products can drive the market growth during forecast period.

Increasing product launches

Controlled release drug delivery systems have allowed pharmaceutical companies to develop innovative formulations that can precisely deliver drugs to the target site over an extended period of time. This has increased new product launches in the market. With controlled release technology, drugs can now be formulated to be released slowly into the body in a pre-designed manner. This enables reducing dosing frequency and maintaining consistent drug levels in the bloodstream over a longer period. Many companies are investing heavily in developing controlled release variants of their blockbuster drugs, which are going off-patent. For example, extended-release versions of opioids like oxycodone and tapentadol helps companies to extend their market exclusivity period and dominate generic competition. For instance, in October 2021, NanoString Technologies, Inc. introduced the Counter ADC Development Panel, a specialized tool for analyzing gene expression tailored for the expanding field of antibody-drug conjugates (ADCs). These ADCs allow precise delivery of potent cytotoxic compounds for cancer treatment. Furthermore, key manufacturers are intensifying their research and development efforts to meet the rising demand for innovative products in targeted drug delivery. For example, in March 2022, AstraZeneca announced  development of advanced drug delivery systems aimed at precise and controlled release of its novel molecules within tissues and cells, aiming to maximize benefits for patients.